Peter Riedell, MD, University of Chicago Medicine, Chicago, IL, comments on the key topics of a talk designed to provide oncologists and bone marrow transplant (BMT) specialists with an overview of CAR-T therapy in diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL). The presentation recapitulated data on the three approved CAR-T products in DLBCL in the third-line setting, axicabtagene ciloleucel (axi-cel), tisagenlecleucel (tisa-cel), and lisocabtagene maraleucel (liso-cel), as well as data from the three pivotal trials comparing these CAR-T therapies to standard of care (SOC) in second line in DLBCL. Advances in MCL were also highlighted and included data showing the benefits of brexucabtagene autoleucel (brexu-cel) in these patients. This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.
Peter Riedell, MD, University of Chicago Medicine, Chicago, IL, provides an overview of recent advances in CAR-T therapy for follicular lymphoma (FL). Axicabtagene ciloleucel (axi-cel) was the first CAR-T therapy to be approved in FL. The promising results of the ZUMA-5 (NCT03105336) and ELARA (NCT03568461) studies are expected to lead to the approval of tisagenlecleucel (tisa-cel) in relapsed/refractory (R/R) FL. Further longitudinal data is required to better understand the impact of CAR-T therapy in patients with FL, as well as to determine which patients are most likely to benefit from this immunotherapy. This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.
Peter M. Riedell, MD, University of Chicago Medicine, Chicago, IL, shares updates from the Phase III ZUMA-7 trial (NCT03391466) of the anti CD19 axicabtagene ciloleucel (axi-cel), a chimeric antigen receptor (CAR) T-cell therapy in patients with relapsed/refractory (r/r) large B-cell lymphoma (LBCL). A superior event-free survival and overall survival were reported in the axi-cel arm and the findings corroborate with data from the Phase III TRANSFORM trial (NCT03575351), demonstrating the potential of CAR T-cell therapy as a second-line option for LBCL. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.